Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; 20210101, Issue: Preprints
- Subject
- Language
- ISSN
- 01406736; 1474547X